Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

ABSTRACT:

Background

The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with diabetic macular oedema (DMO)/neovascular age-related macular degeneration (nAMD) treated with faricimab in the UK. We present results from FARWIDE-DMO for eyes with 12 months of follow-up after faricimab initiation.

Methods

FARWIDE-DMO includes patients with diagnosis of DMO who received ≥1 intravitreal faricimab injection after May 2022 in the diagnosed eye(s) at 1 of 35 UK National Health Service sites. All eyes had ≥12 months of follow-up after faricimab initiation as of July 2024. Treatment-naïve (TN) eyes had no prior anti-VEGF therapy or steroid implant. Previously treated (PT) eyes switched to faricimab. Baseline characteristics, visual acuity (VA) outcomes

SUBMITTER: Peto T 

PROVIDER: S-EPMC12669761 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature